Silencing of AEBP1 inhibits proliferation and promotes apoptosis via the AKT signaling pathway in osteosarcoma

Jia,Cunfeng; Gong,Zhen; Zhang,Lei

doi:10.3892/br.2025.2006

Silencing of AEBP1 inhibits proliferation and promotes apoptosis via the AKT signaling pathway in osteosarcoma

Authors:
- Cunfeng Jia
- Zhen Gong
- Lei Zhang
View Affiliations

Affiliations: Department of Spinal Surgery, Zhangqiu District People's Hospital, Jinan, Shandong 250200, P.R. China
Published online on: May 30, 2025 https://doi.org/10.3892/br.2025.2006
Article Number: 128
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adipocyte enhancer‑binding protein 1 (AEBP1) has emerged as a novel regulator in the tumorigenic progression of various cancers. Despite its significance, the expression and functions of AEBP1 in osteosarcoma (OS) remain largely unexplored. The GEO database was used to screen for novel targets of osteosarcoma and AEBP1 was focused on since its expression and functions in OS remain to be thoroughly elucidated. Thus, the aim of the present study was to investigate the potential biological functions of AEBP1 in OS. UALCAN and CCLE databases were then used to analyze the expression levels of AEBP1. By employing siRNA, AEBP1 was silenced in human OS cells and the expression of AEBP1 at the mRNA and protein levels was assessed through reverse transcription‑quantitave PCR and western blot analysis, respectively. Subsequently, the effects of AEBP1 silencing on the proliferation and apoptosis of human OS cell lines were investigated using MTT, 5‑ethynyl‑2'‑deoxyuridine, clone formation, flow cytometry and TUNEL assays. The results revealed that silencing of AEBP1 inhibited OS cell proliferation, promoted apoptosis, and induced G1 cell cycle arrest in U2OS cells. Mechanistically, AEBP1 was found to be highly expressed in sarcoma and OS cell lines. Silencing of AEBP1 suppressed the expression of p‑AKT and cyclin D1, regulating OS cell proliferation. Furthermore, it reduced the expression levels of Bcl‑2, while promoting Bax expression, thereby enhancing OS cell apoptosis. Notably, the silencing of AEBP1 counteracted the activation of the AKT signaling pathway induced by an activator. In conclusion, the findings of the present study indicated that silencing of AEBP1 suppressed OS proliferation, revealing AEBP1 as a promising therapeutic target for OS treatment.

View Figures

View References

1	Li Z, Li X, Xu D, Chen X, Li S, Zhang L, Chan MTV and Wu WKK: An update on the roles of circular RNAs in osteosarcoma. Cell Prolif. 54(e12936)2021.PubMed/NCBI View Article : Google Scholar
2	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009.PubMed/NCBI View Article : Google Scholar
3	Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S and Strauss SJ: Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer. 131:E508–E517. 2012.PubMed/NCBI View Article : Google Scholar
4	Sheng G, Gao Y, Yang Y and Wu H: Osteosarcoma and metastasis. Front Oncol. 11(780264)2021.
5	Chen C, Xie L, Ren T, Huang Y, Xu J and Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021.PubMed/NCBI View Article : Google Scholar
6	He GP, Muise A, Li AW and Ro HS: A eukaryotic transcriptional repressor with carboxypeptidase activity. Nature. 378:92–96. 1995.PubMed/NCBI View Article : Google Scholar
7	Sugai T, Yamada N, Osakabe M, Hashimoto M, Uesugi N, Eizuka M, Tanaka Y, Sugimoto R, Yanagawa N and Matsumoto T: Microenvironmental markers are correlated with lymph node metastasis in invasive submucosal colorectal cancer. Histopathology. 79:584–598. 2021.PubMed/NCBI View Article : Google Scholar
8	Li S, Liu X, Liu T, Meng X, Yin X, Fang C, Huang D, Cao Y, Weng H, Zeng X and Wang X: Identification of biomarkers correlated with the TNM staging and overall survival of patients with bladder cancer. Front Physiol. 8(947)2017.PubMed/NCBI View Article : Google Scholar
9	Li J, Ruan Y, Zheng C, Pan Y, Lin B, Chen Q and Zheng Z: AEBP1 contributes to breast cancer progression by facilitating cell proliferation, migration, invasion, and blocking apoptosis. Discov Med. 35:45–56. 2023.PubMed/NCBI View Article : Google Scholar
10	Lyons PJ, Mattatall NR and Ro HS: Modeling and functional analysis of AEBP1, a transcriptional repressor. Proteins. 63:1069–1083. 2006.PubMed/NCBI View Article : Google Scholar
11	Ladha J, Sinha S, Bhat V, Donakonda S and Rao SMR: Identification of genomic targets of transcription factor AEBP1 and its role in survival of glioma cells. Mol Cancer Res. 10:1039–1051. 2012.PubMed/NCBI View Article : Google Scholar
12	Liu JY, Jiang L, Liu JJ, He T, Cui YH, Qian F and Yu PW: AEBP1 promotes epithelial-mesenchymal transition of gastric cancer cells by activating the NF-κB pathway and predicts poor outcome of the patients. Sci Rep. 8(11955)2018.PubMed/NCBI View Article : Google Scholar
13	Liu M, Yu Y, Zhang Z, Chen Z, Chen B, Cheng Y, Wei Y, Li J and Shang H: AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: A bioinformatic analyses. Ann Transl Med. 9(1657)2021.PubMed/NCBI View Article : Google Scholar
14	Hou Y, Sun B, Liu W, Yu B, Shi Q, Luo F, Bai Y and Feng H: Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling. Theranostics. 11:555–566. 2021.PubMed/NCBI View Article : Google Scholar
15	Li S, Li C and Fang Z: MicroRNA 214 inhibits adipocyte enhancer-binding protein 1 activity and increases the sensitivity of chemotherapy in colorectal cancer. Oncol Lett. 17:55–62. 2019.PubMed/NCBI View Article : Google Scholar
16	Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P and Khanna C: Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics. 10(625)2009.PubMed/NCBI View Article : Google Scholar
17	Wood RK, Flory AR, Mann MJ, Talbot LJ and Hendershot LM: Secretory defects in pediatric osteosarcoma result from downregulation of selective COPII coatomer proteins. iScience. 25(104100)2022.PubMed/NCBI View Article : Google Scholar
18	Sato S, Tang YJ, Wei Q, Hirata M, Weng A, Han I, Okawa A, Takeda S, Whetstone H, Nadesan P, et al: Mesenchymal tumors can derive from Ng2/Cspg4-expressing pericytes with β-catenin modulating the neoplastic phenotype. Cell Rep. 16:917–927. 2016.PubMed/NCBI View Article : Google Scholar
19	Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.PubMed/NCBI View Article : Google Scholar
20	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Dong M, Yang G, Liu H, Liu X, Lin S, Sun D and Wang Y: Aged black garlic extract inhibits HT29 colon cancer cell growth via the PI3K/Akt signaling pathway. Biomed Rep. 2:250–254. 2014.PubMed/NCBI View Article : Google Scholar
23	Zhu Y, Wu F, Hu J, Xu Y, Zhang J, Li Y, Lin Y and Liu X: LDHA deficiency inhibits trophoblast proliferation via the PI3K/AKT/FOXO1/CyclinD1 signaling pathway in unexplained recurrent spontaneous abortion. FASEB J. 37(e22744)2023.PubMed/NCBI View Article : Google Scholar
24	Mills JN, Rutkovsky AC and Giordano A: Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 41:59–65. 2018.PubMed/NCBI View Article : Google Scholar
25	Politz O, Siegel F, Bärfacker L, Bömer U, Hägebarth A, Scott WJ, Michels M, Ince S, Neuhaus R, Meyer K, et al: BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int J Cancer. 140:449–459. 2017.PubMed/NCBI View Article : Google Scholar
26	Holloway RW, Bogachev O, Bharadwaj AG, McCluskey GD, Majdalawieh AF, Zhang L and Ro HS: Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog signaling. J Biol Chem. 287:39171–39181. 2012.PubMed/NCBI View Article : Google Scholar
27	Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M and Stacey DW: Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene. 24:2599–2612. 2005.PubMed/NCBI View Article : Google Scholar
28	Guo X, Li W, Wang Q and Yang HS: AKT activation by pdcd4 knockdown up-regulates cyclin D1 expression and promotes cell proliferation. Genes Cancer. 2:818–828. 2011.PubMed/NCBI View Article : Google Scholar
29	Wang Z, Wang Y, Wang S, Meng X, Song F, Huo W, Zhang S, Chang J, Li J, Zheng B, et al: Coxsackievirus A6 induces cell cycle arrest in G0/G1 phase for viral production. Front Cell Infect Microbiol. 8(279)2018.PubMed/NCBI View Article : Google Scholar
30	Li S, Juan CX, Feng AM, Bian HL, Liu WD, Zhang GQ, Wang CZ, Cao Q and Zhou GP: Attenuating the abnormally high expression of AEBP1 suppresses the pathogenesis of childhood acute lymphoblastic leukemia via p53-dependent signaling pathway. Eur Rev Med Pharmacol Sci. 23:1184–1195. 2019.PubMed/NCBI View Article : Google Scholar
31	Lin KN, Zhao W, Huang SY and Li H: Grape seed proanthocyanidin extract induces apoptosis of HL-60/ADR cells via the Bax/Bcl-2 caspase-3/9 signaling pathway. Transl Cancer Res. 10:3939–3947. 2021.PubMed/NCBI View Article : Google Scholar
32	Choi JH, Bogenberger JM and Tibes R: Targeting apoptosis in acute myeloid leukemia: Current status and future directions of BCL-2 inhibition with venetoclax and beyond. Target Oncol. 15:147–162. 2020.PubMed/NCBI View Article : Google Scholar